The ABCSF 34 trial in breast cancer vaccine development studied a MUC1-based vaccine, tecemotide, that in combination with neoadjuvant systemic therapy for early breast cancer significantly improved recurrence-free and overall survival [18]. Here, MUC1 is linked to breast cancer.